Pharmidex attending the Global Business Accelerator visit to Switzerland
March 10, 2018

Pharmidex will be attending the Global Business Accelerator Program which is run by the Enterprise Europe Network and supported by Innovate UK.

The Enterprise Europe Network, supported by Innovate UK, are visiting Switzerland to focus on the pharmaceutical technology industry. The chosen companies will have the opportunity to meet pharmaceutical companies and key stakeholders based in Basel and attend ProcureCon Pharma in Zürich for the next three days


The Swiss pharmaceutical sector is a major employer with more than 40,000 people working directly for the industry. If the indirect work created through ancillary industries is included, as many as 172,000 jobs are related to the pharmaceutical industry. In addition, it accounts for up to a third of all Swiss exports, and the productivity of the industry is four times as high as that of the economy as a whole.


Three big clusters – the Lake Geneva area, the Basel region and Zürich-Zug-Lucerne – account for the lion’s share of the gross value added of the Swiss pharmaceutical industry and present many collabartive opputunities for UK companies. 


During the trip Pharmidex will also be attending ProcureCon Pharma, organised by Worldwide Business Research, will take place from 13 to 15 March 2018 in Zürich. Delegates will have the opportunity to join 200 senior procurement professionals from Merck, Astra Zeneca, Roche, Sanofi, Lonza and other world-leading pharmaceutical businesses over three days. 


We look forward to meeting you there.

February 9, 2026
We’re excited to announce that Pharmidex has expanded its analytical capabilities with the addition of the xMAP INTELLIFLEX™ system, a powerful, high-performance platform for multiplex biomarker analysis. This advanced technology enables the simultaneous measurement of multiple analytes from minimal sample volumes, delivering exceptional sensitivity, accuracy and reproducibility. It is ideally suited for complex biological matrices and supports a wide range of applications, from biomarker discovery to translational and preclinical studies.  Our INTELLIFLEX™ supports dual reporter channels to collect more data per sample. 🔬 What this means for our partners and the wider scientific community: • Faster, data-rich insights from fewer samples • Enhanced assay flexibility and scalability • Improved data quality to support confident decision-making • Greater efficiency across drug discovery and development programmes This investment strengthens Pharmidex’s commitment to scientific excellence, allowing us to deliver even more robust, innovative and reliable services to pharma, biotech, CROs and academic collaborators. We look forward to putting this new capability to work in support of better science and better medicines.
February 4, 2026
At Pharmidex , we deliver high-quality LC-MS bioanalysis to support drug development across a wide range of analysis. Our experienced team supports preclinical, translational and clinical studies, providing accurate, reliable data under GLP and GCP to help drive confident decision-making. Learn more about our LC-MS capabilities: https://www.pharmidex.com/Discovery-Bioanalysis
February 2, 2026
Pharmidex offers high-quality Clinical Chemistry services delivering accurate, reliable data to support drug development. Our expert team and robust, quality-driven workflows enable trusted results that help accelerate decision-making and strengthen collaboration with pharma companies, CROs and academic partners. By working together, we support better science and more efficient drug development. 👉 Learn more: https://www.pharmidex.com/Clinical-chemistry
More Posts